A phase IIa study to investigate safety, pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI - IMProveS - (Phase 2 klinische Studie)
Laufzeit: 01.01.2018 - 31.12.2020
Kurzfassung
A phase IIa study to investigate safety, pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI
